Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Table of Contents: Oncotarget’s Volume 12, Issue #12

Oncotarget

June 8, 2021
Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 12. continue reading »

Behind the Study: PRAME Associated with Increased Metastatic Risk

Oncotarget

June 7, 2021
Dr. Matthew G. Field discusses his 2016 study published by Oncotarget, entitled, “Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.” continue reading »

Special Collections by Oncotarget: Skin Cancer & Melanoma

Oncotarget

June 4, 2021
As the summer months begin, Oncotarget launches a new Special Collection of scientific publications directly related to skin cancer and melanoma research. BUFFALO, NY-June 4, 2021 – Skin cancer is a highly preventable cancer (in non-hereditary cases), due to a major risk factor being prolonged exposure to ultraviolet (UV) radiation. However, skin cancer is the most commonly diagnosed cancer in the United States. Predictions show that one in five Americans will be diagnosed with skin cancer by the age of 70.  Melanoma of the skin is the most serious type of skin cancer due to its tendency to spread to… continue reading » continue reading »

Trending With Impact: Novel Urine Protein Biomarkers in Bladder Cancer

Oncotarget

June 3, 2021
Researchers from the University of Houston and UT Southwestern Medical Center conducted a study which aimed to screen urine for potentially useful protein biomarkers of bladder cancer. continue reading »

Can CEA Be Used as a Biomarker for SCCA?

Oncotarget

May 26, 2021
Squamous cell carcinoma of the anal canal (SCCA) most commonly affects women and is closely associated with HPV infection. Researchers search for novel blood-based biomarkers that track responses to SCCA. continue reading »